nach oben

Medical Microbiology and Immunology

Erschienen in:

06.04.2020 | Original Investigation

Luliconazole, a highly effective imidazole, against Fusarium species complexes

verfasst von: Maral Gharaghani, Sahar Hivary, Simin Taghipour, Ali Zarei-Mahmoudabadi

Erschienen in: Medical Microbiology and Immunology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Luliconazole is a new antifungal that was primarily used for the treatment of dermatophytosis. However, some studies have shown that it has excellent efficacy against Aspergillus and Candida species in vitro. The present study aimed to evaluate of luliconazole activity against some Fusarium species complex isolates. In this study, 47 isolates of Fusarium were tested against several antifungals including luliconazole. All species were identified using morphology features, and PCR sequencing and antifungal susceptibility were performed according to CLSIM38 A3 guideline. Our results revealed that luliconazole has a very low minimum inhibitory concentration value (0.0078–1 µg/ml) in comparison with other tested antifungals. Amphotericin B had a poor effect with a high MIC₉₀ (64 µg/ml), followed by terbinafine (32 µg/ml), posaconazole (16 µg/ml), caspofungin (16 µg/ml), voriconazole (4 µg/ml), and itraconazole (4 µg/ml). Overall, our findings indicated that luliconazole has great activity against environmental and clinical Fusarium species complexes in comparison to tested antifungals.

Gupta AK, Foley KA, Versteeg SG (2017) New antifungal agents and new formulations against dermatophytes. Mycopathologia 182(1–2):127–141. https://doi.org/10.1007/s11046-016-0045-0PubMedCrossRef

Jarratt M, Jones T, Adelglass J et al (2014) Efficacy and safety of once-daily luliconazole 1% cream in patients ≥ 12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind, vehicle-controlled study. J Drugs Dermatol 13(7):838–846PubMed

Jones T, Tavakkol A (2013) Safety and tolerability of luliconazole solution 10% in patients with moderate to severe distal subungual onychomycosis. Antimicrob Agents Chemother 57(6):2684–2689. https://doi.org/10.1128/AAC.02370-12PubMedPubMedCentralCrossRef

Watanabe S, Takahashi H, Nishikawa T et al (2006) A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. Mycoses 49(3):236–241. https://doi.org/10.1111/j.1439-0507.2006.01218.xPubMedCrossRef

Wiederhold NP, Fothergill AW, McCarthy DI, Tavakkol A (2014) Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis. Antimicrob Agents Chemother 58(6):3553–3555. https://doi.org/10.1128/AAC.02706-13PubMedPubMedCentralCrossRef

Shokoohi GR, Badali H, Mirhendi H et al (2017) In vitro activities of luliconazole, lanoconazole, and efinaconazole compared with those of five antifungal drugs against melanized fungi and relatives. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.00635-17PubMedPubMedCentralCrossRef

Abastabar M, Rahimi N, Meis JF et al (2016) Potent activities of novel imidazoles lanoconazole and luliconazole against a collection of azole-resistant and -susceptible Aspergillus fumigatus strains. Antimicrob Agents Chemother 60(11):6916–6919. https://doi.org/10.1128/AAC.01193-16PubMedPubMedCentralCrossRef

Zargaran M, Taghipour S, Kiasat N et al (2017) Luliconazole, an alternative antifungal agent against Aspergillus terreus. J Mycol Med 27(3):351–356. https://doi.org/10.1016/j.mycmed.2017.04.011PubMedCrossRef

Omran SM, Taghizadeh-Armaki M, Zarrinfar H et al (2019) In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis. J Infect Chemother 25(2):157–160. https://doi.org/10.1016/j.jiac.2018.07.018PubMedCrossRef

10.

Todokoro D, Suzuki T, Tamura T et al (2019) Efficacy of luliconazole against broad-range filamentous fungi including Fusarium solani species complex causing fungal keratitis. Cornea 38(2):238–242. https://doi.org/10.1097/ico.0000000000001812PubMedCrossRef

11.

Taghipour S, Kiasat N, Shafiei S et al (2018) Luliconazole, a new antifungal against Candida species isolated from different sources. J Mycol Med 28(2):374–378. https://doi.org/10.1016/j.mycmed.2017.11.004PubMedCrossRef

12.

Jain P, Gupta V, Misra A et al (2011) Current status of Fusarium infection in human and animal. Asian J Anim Vet Adv 6:201–227. https://doi.org/10.3923/ajava.2011.201.227CrossRef

13.

Dabas Y, Bakhshi S, Xess I (2016) Fatal cases of bloodstream infection by Fusarium solani and review of published literature. Mycopathologia 181(3–4):291–296. https://doi.org/10.1007/s11046-015-9960-8PubMedCrossRef

14.

Schwartz KL, Sheffield H, Richardson SE, Sung L, Morris SK (2015) Invasive fusariosis: a single pediatric center 15-year experience. J Pediatr Infect Dis Soc 4(2):163–170. https://doi.org/10.1093/jpids/pit080CrossRef

15.

Horn DL, Freifeld AG, Schuster MG et al (2014) Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance((R)) registry. Mycoses 57(11):652–658. https://doi.org/10.1111/myc.12212PubMedCrossRef

16.

Dignani MC, Anaissie E (2004) Human fusariosis. Clin Microbiol Infect 10(Suppl 1):67–75. https://doi.org/10.1111/j.1470-9465.2004.00845.xPubMedCrossRef

17.

Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E (2011) Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) 90(1):69–80. https://doi.org/10.1097/MD.0b013e318207612dCrossRef

18.

Labois A, Gray C, Lepretre S (2011) Successful treatment of disseminated fusariosis with voriconazole in an acute lymphoblastic leukaemia patient. Mycoses 54(Suppl 4):8–11. https://doi.org/10.1111/j.1439-0507.2011.02136.xPubMedCrossRef

19.

Mayr U, Rasch S, Schmid RM, Huber W, Lahmer T (2017) First description of spontaneous fungal peritonitis caused by Fusarium solani in a critically ill patient with liver cirrhosis. New Microbes New Infect 20:16–17. https://doi.org/10.1016/j.nmni.2017.08.003PubMedPubMedCentralCrossRef

20.

Nucci M, Varon AG, Garnica M et al (2013) Increased incidence of invasive fusariosis with cutaneous portal of entry. Braz Emerg Infect Dis 19(10):1567–1572. https://doi.org/10.3201/eid1910.120847CrossRef

21.

Carlesse F, Amaral AC, Goncalves SS et al (2017) Outbreak of Fusarium oxysporum infections in children with cancer: an experience with 7 episodes of catheter-related fungemia. Antimicrob Resist Infect Control 6:93. https://doi.org/10.1186/s13756-017-0247-3PubMedPubMedCentralCrossRef

22.

Ranawaka RR, Nagahawatte A, Gunasekara TA (2015) Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases. Int J Dermatol 54(11):1275–1282. https://doi.org/10.1111/ijd.12906PubMedCrossRef

23.

Muraosa Y, Oguchi M, Yahiro M et al (2017) Epidemiological study of Fusarium species causing invasive and superficial fusariosis in Japan. Med Mycol J 58(1):E5–E13. https://doi.org/10.3314/mmj.16-00024PubMedCrossRef

24.

Varon AG, Nouer SA, Barreiros G et al (2014) Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis. J Infect 68(1):85–89. https://doi.org/10.1016/j.jinf.2013.08.011PubMedCrossRef

25.

Ribas R, Daniela A, Spolti P et al (2016) Is the emergence of fungal resistance to medical triazoles related to their use in the agroecosystems? A mini review. Braz J Microbiol 47(4):793–799. https://doi.org/10.1016/j.bjm.2016.06.006CrossRef

26.

Lalitha P, Shapiro BL, Srinivasan M et al (2007) Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol 125(6):789–793. https://doi.org/10.1001/archopht.125.6.789PubMedCrossRef

27.

Ozturk F, Yavas GF, Kusbeci T et al (2007) Efficacy of topical caspofungin in experimental fusarium keratitis. Cornea 26(6):726–728. https://doi.org/10.1097/ICO.0b013e3180553b9dPubMedCrossRef

28.

Taylan Sekeroglu H, Erdem E, Yagmur M et al (2012) Successful medical management of recalcitrant Fusarium solani keratitis: molecular identification and susceptibility patterns. Mycopathologia 174(3):233–237. https://doi.org/10.1007/s11046-012-9542-yPubMedCrossRef

29.

Scher RK, Nakamura N, Tavakkol A (2014) Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses 57(7):389–393. https://doi.org/10.1111/myc.12168PubMedCrossRef

30.

Gupta AK, Daigle D (2016) A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. Infect Drug Resist 9:1–6. https://doi.org/10.2147/IDR.S61998PubMedPubMedCentralCrossRef

31.

Geiser DM, del Mar J-GM, Kang S et al (2004) FUSARIUM-ID v. 1.0: a DNA sequence database for identifying Fusarium. Eur J Plant Pathol 110(5–6):473–479. https://doi.org/10.1023/B:EJPP.0000032386.75915.a0CrossRef

32.

CLSI (2017) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. CLSI document M38-3rd. Clinical and Laboratory Standards Institute, Wayne, PA

33.

Espinel-Ingroff A, Colombo AL, Cordoba S et al (2016) International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for Fusarium species identified by molecular methods for the CLSI Broth Microdilution method. Antimicrob Agents Chemother 60(2):1079–1084. https://doi.org/10.1128/AAC.02456-15PubMedPubMedCentralCrossRef

34.

Draelos ZD, Vlahovic TC, Gold MH, Parish LC, Korotzer A (2014) A randomized, double-blind, vehicle-controlled trial of luliconazole cream 1% in the treatment of interdigital tinea pedis. J Clin Aesthet Dermatol 7(10):20–27PubMedPubMedCentral

35.

Watanabe S, Kishida H, Okubo A (2017) Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: a multicenter, double-blind, randomized phase III study. J Dermatol 44(7):753–759. https://doi.org/10.1111/1346-8138.13816PubMedCrossRef

36.

Koga H, Nanjoh Y, Kaneda H, Yamaguchi H, Tsuboi R (2012) Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis. Antimicrob Agents Chemother 56(6):3138–3143. https://doi.org/10.1128/AAC.05255-11PubMedPubMedCentralCrossRef

37.

Maeda J, Nanjoh Y, Koga H et al (2016) In vitro antifungal activity of luliconazole against Trichophyton spp. Med Mycol J 57(1):J1–6. https://doi.org/10.3314/mmj.57.J1PubMedCrossRef

38.

Saunders J, Maki K, Koski R, Nybo SE (2017) Tavaborole, efinaconazole, and luliconazole: three new antimycotic agents for the treatment of dermatophytic fungi. J Pharm Pract 30(6):621–630. https://doi.org/10.1177/0897190016660487PubMedCrossRef

39.

Koga H, Nanjoh Y, Makimura K, Tsuboi R (2009) In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol 47(6):640–647. https://doi.org/10.1080/13693780802541518PubMedCrossRef

40.

Abastabar M, Al-Hatmi AM, Moghaddam MV et al (2018) Potent activities of luliconazole, lanoconazole, and eight comparators against molecularly characterized Fusarium species. Antimicrob Agents Chemother 62(5):e00009–18. https://doi.org/10.1128/AAC.00009-18PubMedPubMedCentralCrossRef

41.

Al-Hatmi A (2016) Phylogeny, diagnostics and antifungal susceptibility of clinically relevant Fusarium species: Ph.D. thesis. University of Amsterdam, Amsterdam, the Netherlands. http://hdl.handle.net/11245/1.547668)

42.

Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, de Hoog GS, Meis JF (2014) Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother 70(4):1068–1071. https://doi.org/10.1093/jac/dku505PubMedCrossRef

43.

Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, Mellado E, Rodríguez-Tudela JL (2008) Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 61(4):805–809. https://doi.org/10.1093/jac/dkn022PubMedCrossRef

44.

Taj-Aldeen SJ, Salah H, Al-Hatmi AM et al (2016) In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method. Diagn Microbiol Infect Dis 85(4):438–443. https://doi.org/10.1016/j.diagmicrobio.2016.05.006PubMedCrossRef

45.

Spader TB, Venturini TP, Cavalheiro AS et al (2011) In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Mycoses 54(2):131–136. https://doi.org/10.1111/j.1439-0507.2009.01773.xPubMedCrossRef

46.

Tupaki-Sreepurna A, Al-Hatmi AM, Kindo AJ, Sundaram M, de Hoog GS (2017) Multidrug-resistant Fusarium in keratitis: a clinico-mycological study of keratitis infections in Chennai, India. Mycoses 60(4):230–233. https://doi.org/10.1111/myc.12578PubMedCrossRef

47.

Al-Hatmi AM, Meis JF, de Hoog GS (2016) Fusarium: molecular diversity and intrinsic drug resistance. PLoS Pathog 12(4):e1005464. https://doi.org/10.1371/journal.ppat.1005464PubMedPubMedCentralCrossRef

48.

Katiyar SK, Edlind TD (2009) Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother 53(5):1772–1778. https://doi.org/10.1128/AAC.00020-09PubMedPubMedCentralCrossRef

49.

Lass-Florl C, Mayr A, Perkhofer S et al (2008) Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 52(10):3637–3641. https://doi.org/10.1128/AAC.00662-08PubMedPubMedCentralCrossRef

50.

Taj-Aldeen S (2017) Reduced multidrug susceptibility profile is a common feature of opportunistic Fusarium species: Fusarium multi-drug resistant pattern. J Fungi 3(18):1–15. https://doi.org/10.3390/jof3020018CrossRef

51.

Raad II, Hachem RY, Herbrecht R et al (2006) Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42(10):1398–1403. https://doi.org/10.1086/503425PubMedCrossRef

52.

Guarro J (2013) Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis 32(12):1491–1500. https://doi.org/10.1007/s10096-013-1924-7PubMedCrossRef

53.

Venturini TP, Chassot F, Loreto ES et al (2016) Antifungal activities of diphenyl diselenide and ebselen alone and in combination with antifungal agents against Fusarium spp. Med Mycol 54(5):550–555. https://doi.org/10.1093/mmy/myv120PubMedCrossRef

Titel: Luliconazole, a highly effective imidazole, against Fusarium species complexes
verfasst von: Maral Gharaghani
Sahar Hivary
Simin Taghipour
Ali Zarei-Mahmoudabadi
Publikationsdatum: 06.04.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Medical Microbiology and Immunology / Ausgabe 5/2020
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-020-00672-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

The effect of KIR and HLA polymorphisms on dengue infection and disease severity in northeastern Thais

Outer inflammatory protein of Helicobacter pylori impacts IL-8 expression, adherence, cell apoptosis and cell cycle of gastric cells independent of its copy number

Correction to: A role for tetraspanin proteins in regulating fusion induced by Burkholderia thailandensis

Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154+Aspergillus fumigatus specific T-cell quantification

Association of serum C-reactive protein level and polymorphisms with susceptibility to dengue infection and severe clinical outcome among eastern Indian patients